Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries

Figures & data

Figure 1. Example calculation for PHiD-CV for Pakistan in 2019.

mo: months; PHiD-CV: pneumococcal polysaccharide protein D-conjugate vaccine. The total number of deaths averted over a 5-y period correspond to the sum of each cell of the same color, i.e. Total deaths averted for 2019 is 31,230, and is the sum of each dark blue cell (10,085 + 5,824 + 5,107 + 5,107 + 5,107 = 31,230)

Table 1. Data retrieved from databases and literature for RD vaccination.

Source	Data retrieved
GSK database	Doses delivered per year per country
Gavi-UNICEF estimates	Wastage (%) among single-dose and multi-dose vials^Citation23
World Bank database	Overall deaths in children under 5 y old by year and country^Citation17
Published literature	Specific number of RD-related deaths in children under 5 old by year and country^Citation13,Citation14,Citation19,Citation20
Published literature	Number of severe events of RD-related disease per specific death per country^Citation21,Citation22
Published literature	Vaccine effect on specific deaths and severe events per country^Citation24
Published literature	Proportional disease distribution by 1-y age group up to 5 y old^Citation25

RD: rotavirus disease, UNICEF: United Nations Children’s Fund.

Figure 2. Number of children estimated to be vaccinated with HRV and PHiD-CV across Gavi-supported countries from 2009–2019.

HRV: human rotavirus vaccine; PHiD-CV: pneumococcal polysaccharide protein D-conjugate vaccine

Figure 3. Estimate of number of severe RD and PD disease cases averted by HRV and PHiD-CV vaccination per year in Gavi-supported countries.

PHiD-CV impact not considered for any doses delivered before study period (2011 − 2019). HRV: human rotavirus vaccine; PD: pneumococcal disease; PHiD-CV: pneumococcal polysaccharide protein D-conjugate vaccine; RD: rotavirus disease

Figure 4. Estimate of number of RD and PD deaths averted by HRV and PHiD-CV vaccination per year in Gavi-supported countries.

PHiD-CV impact not considered for any doses delivered before study period (2011 − 2019). HRV: human rotavirus vaccine; PD: pneumococcal disease; PHiD-CV: pneumococcal polysaccharide protein D-conjugate vaccine; RD: rotavirus disease

Figure 5. Total estimated severe RD cases and deaths averted for all children vaccinated during study period and followed up until 5 y of age in selected countries.

RD: rotavirus disease

Figure 6. Total estimated severe PD cases and deaths averted for all children vaccinated during study period and followed up until 5 y of age in selected countries.

PHiD-CV impact not considered for any doses delivered before study period (2011 − 2019). PD: pneumococcal disease; PHiD-CV: pneumococcal polysaccharide protein D-conjugate vaccine

Parmar D, Baruwa EM, Zuber P, Kone S. Impact of wastage on single and multi-dose vaccine vials: implications for introducing pneumococcal vaccines in developing countries. Hum Vaccin. 2010;6(3):270–78. doi:10.4161/hv.6.3.10397.

 Web of Science ®Google Scholar

The World Bank. Mortality rate, under-5 (per 1,000 live births). Washington DC: UN Inter-agency Group for Child Mortality Estimation; 2022 [accessed 2021 Mar 17]. https://data.worldbank.org/indicator/SH.DYN.MORT.

 Google Scholar

Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000-2013. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2016;62(Suppl 2):S96–s105. doi:10.1093/cid/civ1013.

 PubMed Web of Science ®Google Scholar

Clark A, Black R, Tate J, Roose A, Kotloff K, Lam D, Blackwelder W, Parashar U, Lanata C, Kang G, et al. Estimating global, regional and national rotavirus deaths in children aged <5 years: current approaches, new analyses and proposed improvements. PloS one. 2017;12:e0183392. doi:10.1371/journal.pone.0183392.

 PubMed Web of Science ®Google Scholar

GBD Diarrhoeal Diseases Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–71. doi:10.1016/S0140-6736(14)61682-2.

 PubMed Web of Science ®Google Scholar

Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PloS one. 2013;8:e72788. doi:10.1371/journal.pone.0072788.

 PubMed Web of Science ®Google Scholar

GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis. 2017;17(9):909–48. doi:10.1016/S1473-3099(17)30276-1.

 PubMed Web of Science ®Google Scholar

Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12(2):304–06. doi:10.3201/eid1202.050006.

 PubMed Web of Science ®Google Scholar

Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006-2016. Clinical Infectious Diseases. 2017;65(5):840–50. doi:10.1093/cid/cix369.

 PubMed Web of Science ®Google Scholar

Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81(3):197–204. [Accessed 2022 Nov 30]. https://apps.who.int/iris/bitstream/handle/10665/268903/PMC2572419.pdf?sequence=1&isAllowed=y

 PubMed Web of Science ®Google Scholar